News

Included in the 2005 results was a charge of $124 million before a tax benefit of $6 million, or 8 cents per share, related to an R&D payment.

Net income for the Q3 was $940 million compared to $1.4 billion for the comparable quarter last year. Merck reported worldwide sales of $5.4 billion for the quarter,

The approval makes Zaditor the only OTC drop to treat eye itch associated with pollen, ragweed, grass, animal hair and dander without the potentially negative effects of a

National Institute of Allergy and Infectious Diseases (NIAID) virologist Dr Jeffrey Cohen, and NIAID research fellow Dr Qingxue Li, discovered that a surface protein of varicella-zoster virus attaches

Revenue grew to $12.28 billion in the quarter and the company said that its in-line products performed well in a tough operating environment. However, Pfizer warned its shareholders

The approval is based on one-year data from a trial, which found that patients receiving Remicade were nearly three times as likely as patients in the placebo group

“Given the robust efficacy and safety results observed in our recently completed Alzheimer’s disease clinical study of Dimebon, we are excited about Dimebon’s potential to benefit Huntington’s disease

The grant will support the patient-related costs of the company’s ongoing phase II clinical trial of PTC124. PTC initiated the phase II clinical trial of PTC124 in January

Durect said that Voyager had ended the trials “in order to get an earlier look at potential efficacy from over 600 accrued patients.” “We look forward to this